导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 27.09% | 108/4773 |
| 近一周 | -2.74% | 2966/5462 |
| 近一月 | -5.23% | 3113/5421 |
| 近一季 | -22.33% | 5116/5209 |
| 近半年 | 21.27% | 119/4920 |
| 近一年 | 52.01% | 48/4366 |
| 近两年 | 285.12% | 5/2954 |
| 近三年 | 269.01% | 3/2253 |
| 成立以来 | 223.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.93% 630/4961 |
68.08% 305/5312 |
- - |
- - |
| 2025 | 126.13% 1/4813 |
-7.16% 3427/3635 |
14.87% 39/4076 |
84.01% 1/4524 |
15.23% 67/4813 |
| 2024 | 31.56% 95/3463 |
11.37% 26/2808 |
1.98% 420/3014 |
11.98% 2437/3129 |
3.45% 818/3463 |
| 2023 | 25.83% 10/2656 |
28.97% 74/2280 |
23.20% 1/2385 |
-14.73% 2193/2515 |
-7.13% 2059/2655 |
| 2022 | -26.70% 1425/2207 |
-19.13% 1432/1919 |
2.49% 1295/2016 |
-12.66% 756/2113 |
1.25% 1326/2208 |
| 2021 | 7.37% 499/1822 |
-7.14% 1057/1255 |
6.36% 757/1330 |
-6.05% 897/1466 |
15.71% 59/1822 |
| 2020 | -2.27% 956/1250 |
0.17% 169/1028 |
9.16% 802/1067 |
-3.54% 1092/1164 |
-7.34% 1155/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.62% 697/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证全指通信设备ETF VS. 长安沪深300非周期A(740101) |